The Company's operating performance over the last 24 months demonstrates a strategic and successful pivot towards higher-value manufacturing, particularly within the MedTech sector, which has been crucial in improving its economic performance despite challenges in other segments. This shift is evident in the robust growth of its core manufacturing revenue, significant expansion in gross profit margins driven by manufacturing efficiency, and a promising increase in order book and strategic project wins, indicating strong future demand and market positioning. While some regional disparities exist, the overall trend points to enhanced operational efficiency and a stronger foundation for sustainable growth.

Here are the three most important operating metrics materially impacting the Company's economic performance:

### 1. Manufacturing Revenue Growth (Segmental & Geographic Breakdown)

*   **Definition and Relevance:** This metric measures the year-over-year or half-over-half change in revenue generated specifically from the Company's core manufacturing operations, broken down by key geographic regions (Singapore, Malaysia, China). It is highly relevant as it reflects the underlying volume demand for the Company's products and services, its ability to secure new business, and the performance of its strategic regional operations. Growth in this segment indicates success in capturing market share and responding to market opportunities, particularly given the Company's strategic focus on high-precision manufacturing.

*   **Historical Data (Last 24 months):**
    *   **FY2024 Manufacturing Revenue:** S$114.9 million, representing a 10.5% growth from FY2023 [FACT: Revenue from continuing operations (manufacturing) grew 10.5% to S$114.9 million] | [SOURCE: Fu Yu 24 AR_m.md, p.5].
    *   **1H2024 Manufacturing Revenue:** S$54.8 million [FACT: Manufacturing revenue rose to S$54.8 million from S$52.6 million] | [SOURCE: Fuyu Pres H124_m.md, p.5].
        *   Singapore Manufacturing Revenue (1H2024): S$21.0 million, an increase of 6.6% [FACT: Singapore manufacturing revenue increased 6.6% to S$21.0 million] | [SOURCE: Fuyu Pres H124_m.md, p.5].
        *   Malaysia Manufacturing Revenue (1H2024): S$17.8 million, an increase of 39.1% [FACT: Malaysia manufacturing revenue increased 39.1% to S$17.8 million] | [SOURCE: Fuyu Pres H124_m.md, p.5].
        *   China Manufacturing Revenue (1H2024): S$16.0 million, a decline of 20.4% [FACT: China manufacturing revenue declined 20.4% to S$16.0 million] | [SOURCE: Fuyu Pres H124_m.md, p.5].
    *   **2H2024 Manufacturing Revenue:** S$60.1 million (derived: S$114.9 million (FY2024) - S$54.8 million (1H2024)) | [SOURCE: Fu Yu 24 AR_m.md, p.5, Fuyu Pres H124_m.md, p.5].
        *   Singapore contributed S$46.2 million to manufacturing revenue in FY2024 [FACT: Singapore operations contributed S$46.2 million to manufacturing revenue] | [SOURCE: Fu Yu 24 AR_m.md, p.5], implying S$25.2 million in 2H2024.
        *   Malaysia contributed S$36.6 million to manufacturing revenue in FY2024 [FACT: Malaysia operations contributed S$36.6 million to manufacturing revenue] | [SOURCE: Fu Yu 24 AR_m.md, p.5], implying S$18.8 million in 2H2024.
        *   China contributed 27.9% of total manufacturing revenue in FY2024, which is S$32.07 million (S$114.9 million * 0.279) [FACT: China operations contributed 27.9% of total manufacturing revenue] | [SOURCE: Fu Yu 24 AR_m.md, p.5], implying S$16.07 million in 2H2024.
    *   **1H2023 Manufacturing Revenue:** S$52.6 million (as 1H2024 manufacturing revenue rose from this figure) [FACT: Manufacturing revenue rose to S$54.8 million from S$52.6 million] | [SOURCE: Fuyu Pres H124_m.md, p.5].
        *   Singapore Manufacturing Revenue (1H2023): S$19.7 million (derived: S$21.0 million / 1.066) | [SOURCE: Fuyu Pres H124_m.md, p.5].
        *   Malaysia Manufacturing Revenue (1H2023): S$12.8 million (derived: S$17.8 million / 1.391) | [SOURCE: Fuyu Pres H124_m.md, p.5].
        *   China Manufacturing Revenue (1H2023): S$20.1 million (derived: S$16.0 million / (1-0.204)) | [SOURCE: Fuyu Pres H124_m.md, p.5].
    *   **2H2023 Manufacturing Revenue:** S$51.4 million (derived: S$104.0 million (FY2023 total, based on 10.5% growth) - S$52.6 million (1H2023)) | [SOURCE: Fu Yu 24 AR_m.md, p.5, Fuyu Pres H124_m.md, p.5].

*   **Benchmarking:** No explicit competitor or industry average data is available in the provided facts for benchmarking.

*   **Drivers of Performance:** The overall 10.5% growth in manufacturing revenue for FY2024 [Fu Yu 24 AR_m.md, p.5] was driven by strong performance in Malaysia and Singapore, which compensated for a decline in China. Malaysia's manufacturing revenue significantly increased by 39.1% in 1H2024 [Fuyu Pres H124_m.md, p.5], indicating robust demand or successful market penetration in that region. Singapore manufacturing also saw positive growth of 6.6% in 1H2024 [Fuyu Pres H124_m.md, p.5], likely bolstered by the strategic investments in the Smart Factory and the launch of Fu Yu Biomedical in 2023 [Fu Yu 24 AR_m.md, p.3], attracting new high-precision projects. Conversely, China's manufacturing revenue declined by 20.4% in 1H2024 [Fuyu Pres H124_m.md, p.5], suggesting challenging market conditions or a shift in focus away from that region. The substantial increase in 2H2024 manufacturing revenue compared to 1H2024 (S$60.1 million vs S$54.8 million) indicates strong momentum towards the end of the year.

*   **Sustainability of Current Performance Trend:** The positive trend in overall manufacturing revenue, particularly in Singapore and Malaysia, appears sustainable given the company's strategic shift towards high-precision and MedTech segments (e.g., Fu Yu Biomedical launched in 2023 [Fu Yu 24 AR_m.md, p.3], new projects with international biomedical companies and CDMOs in 1H2024 [Fuyu Pres H124_m.md, p.11]). The increased order book [Fu Yu 24 AR_m.md, p.6] further supports future revenue growth. However, the continued decline in China could be a drag if not managed effectively, but its relative contribution has decreased (27.9% of total manufacturing revenue in FY2024) [Fu Yu 24 AR_m.md, p.5].

*   **Quantified Financial Impact:** The 10.5% growth in manufacturing revenue to S$114.9 million in FY2024 [Fu Yu 24 AR_m.md, p.5] was the primary driver of the Group's overall 0.5% revenue increase to S$191.3 million [FACT: Group's overall revenue increased 0.5% to S$191.3 million] | [SOURCE: Fu Yu 24 AR_m.md, p.8], especially as the supply chain management services segment declined to S$76.4 million [FACT: Revenue from the supply chain management services segment declined to S$76.4 million] | [SOURCE: Fu Yu 24 AR_m.md, p.8]. This growth in the higher-margin manufacturing segment also contributed significantly to the 27.5% increase in gross profit from continuing operations to S$15.5 million [FACT: Gross profit for continuing operations increased 27.5% to S$15.5 million] | [SOURCE: Fu Yu 24 AR_m.md, p.5].

*   **Due Diligence Questions:**
    1.  What is the underlying demand driver for the significant growth in Malaysia's manufacturing revenue in 1H2024, and what steps are being taken to mitigate the continued decline in China's manufacturing revenue?
    2.  Can the company provide a breakdown of manufacturing revenue by end-market (e.g., medical, consumer electronics, automotive) to assess diversification and exposure to growth sectors, particularly regarding the contribution from new biomedical projects?

### 2. Gross Profit Margin (Segmental)

*   **Definition and Relevance:** Gross Profit Margin (GPM) represents the percentage of revenue left after deducting the cost of goods sold. Analyzing GPM by segment (manufacturing vs. supply chain management services) reveals the profitability of each core business line and the Company's ability to manage production costs, optimize pricing, and enhance operational efficiency. It's a direct indicator of "unit margins" and overall unit economics.

*   **Historical Data (Last 24 months):**
    *   **FY2024 Overall GPM:** 8.9%, up from 7.0% in FY2023 [FACT: Overall gross profit margin increased to 8.9% from 7.0%] | [SOURCE: Fu Yu 24 AR_m.md, p.8].
        *   Manufacturing Segment GPM (FY2024): 13.5%, up from 11.7% in FY2023 [FACT: Gross profit margin for continuing operations improved to 13.5% from 11.7%] | [SOURCE: Fu Yu 24 AR_m.md, p.5].
        *   Supply Chain Management Services Segment GPM (FY2024): 1.9% [FACT: Supply chain management services segment gross profit margin was 1.9%] | [SOURCE: Fu Yu 24 AR_m.md, p.8].
    *   **1H2024 Overall GPM:** 6.7% [FACT: GPM stood at 6.7%] | [SOURCE: Fuyu Pres H124_m.md, p.6].
    *   **2H2024 Overall GPM:** 13.2% [FACT: Group's gross profit margin was 13.2%] | [SOURCE: Fu Yu FS Q424_m.md, p.29].
    *   **FY2023 Overall GPM:** 7.0% [FACT: Overall gross profit margin increased to 8.9% from 7.0%] | [SOURCE: Fu Yu 24 AR_m.md, p.8].
        *   Manufacturing Segment GPM (FY2023): 11.7% [FACT: Gross profit margin for continuing operations improved to 13.5% from 11.7%] | [SOURCE: Fu Yu 24 AR_m.md, p.5].

*   **Benchmarking:** No explicit competitor or industry average data is available in the provided facts for benchmarking.

*   **Drivers of Performance:** The significant improvement in overall gross profit margin from 7.0% in FY2023 to 8.9% in FY2024 [Fu Yu 24 AR_m.md, p.8] was primarily driven by the manufacturing segment, which saw its GPM improve from 11.7% to 13.5% [Fu Yu 24 AR_m.md, p.5]. This improvement suggests better cost control, potentially higher value-added projects, or improved pricing power. The supply chain management services segment, while contributing to overall revenue, maintained a very low GPM of 1.9% in FY2024 [Fu Yu 24 AR_m.md, p.8], indicating its low-margin nature. The GPM trajectory within FY2024 shows a strong recovery in 2H2024 (13.2%) compared to 1H2024 (6.7%) [Fu Yu FS Q424_m.md, p.29, Fuyu Pres H124_m.md, p.6], which could be due to a more favorable product mix, successful cost-reduction initiatives, or increased utilization in the latter half of the year. The Company's efforts to increase automation [FACT: The Group aims to increase automation levels of its toolroom to reduce downtime by 40% compared to a typical facility] | [SOURCE: Fu Yu 24 AR_m.md, p.7] and improve operational efficiency by replacing hydraulic machinery [FACT: The Group is systematically replacing hydraulic machinery with electrically powered alternatives to improve operational efficiency and reduce oil consumption] | [SOURCE: Fu Yu 24 AR_m.md, p.47] likely contribute to this margin expansion.

*   **Sustainability of Current Performance Trend:** The positive trend in manufacturing GPM is likely sustainable, supported by the ongoing strategic shift towards high-precision and MedTech products, which typically command higher margins [Fu Yu 24 AR_m.md, p.3, p.7]. Further improvements are expected from increased automation levels and efficiency initiatives [Fu Yu 24 AR_m.md, p.7, p.47]. The Enterprise Resource Planning (ERP) integrated cloud-based IT platform completed most of its testing in FY2024 [FACT: Enterprise Resource Planning (ERP) integrated cloud-based IT platform completed most of its testing] | [SOURCE: Fu Yu 24 AR_m.md, p.7] and recent transition to a paperless mould-making platform [FACT: The Group has recently transitioned to an integrated cloud-based platform for completely paperless mould-making] | [SOURCE: Fu Yu 24 AR_m.md, p.47] should further enhance operational efficiency and cost management, supporting margin expansion.

*   **Quantified Financial Impact:** The increase in manufacturing GPM from 11.7% to 13.5% in FY2024 [Fu Yu 24 AR_m.md, p.5], coupled with the 10.5% revenue growth in that segment, significantly contributed to the 27.5% increase in gross profit for continuing operations to S$15.5 million [Fu Yu 24 AR_m.md, p.5]. This margin expansion was crucial in narrowing the net loss from continuing operations to S$1.2 million from S$7.6 million in FY2024 [FACT: Net loss from continuing operations narrowed to S$1.2 million from S$7.6 million] | [SOURCE: Fu Yu 24 AR_m.md, p.5], and reversing the Singapore manufacturing operations PBT from a loss of S$6.9 million to a profit of S$1.2 million [FACT: Singapore manufacturing operations posted a PBT of S$1.2 million, reversing a loss before tax of S$6.9 million] | [SOURCE: Fu Yu 24 AR_m.md, p.29]. The 2H2024 GPM improvement to 13.2% from 1H2024's 6.7% contributed to the Group's net loss narrowing to S$3.964 million in 2H24 [FACT: Group's net loss was S$3.964 million] | [SOURCE: Fu Yu FS Q424_m.md, p.4] from a net profit of S$0.1 million in 1H2024 [FACT: Net profit of S$0.1 million] | [SOURCE: Fuyu Pres H124_m.md, p.6].

*   **Due Diligence Questions:**
    1.  What specific initiatives (e.g., pricing strategy, product mix shift, cost efficiencies) primarily drove the substantial GPM improvement in 2H2024, and what are the detailed assumptions for maintaining or improving this trend in FY2025?
    2.  Given the low margin of the supply chain management services segment (1.9% in FY2024), what is the long-term strategy for this segment, and how does it contribute to the overall manufacturing business (e.g., customer stickiness, integrated solutions)?

### 3. Order Book Growth and Strategic Project Wins

*   **Definition and Relevance:** This metric assesses the Company's future revenue potential by tracking the growth in its order book and the successful acquisition of new, strategically important projects, particularly in emerging high-growth sectors like MedTech. It serves as a leading indicator of future volumes, market penetration, and the success of the Company's strategic initiatives to move up the value chain. It implicitly relates to "volumes" and future "market share" within targeted high-value segments.

*   **Historical Data (Last 24 months):**
    *   **Order Book Growth:** Increased 20% year-on-year at the end of FY2024 [FACT: Order book at the end of FY2024 increased 20% year-on-year] | [SOURCE: Fu Yu 24 AR_m.md, p.6]. (No specific prior period order book values provided).
    *   **Strategic Project Wins (1H2024):**
        *   Secured new projects with an international biomedical company to produce microfluidic chips (used in medical diagnostic devices) [FACT: Group secured new projects with an international biomedical company to produce microfluidic chips (used in medical diagnostic devices)] | [SOURCE: Fuyu Pres H124_m.md, p.11].
        *   Signed a partnership with a Contract Development and Manufacturing Organisation (CDMO) to produce high-precision tools used to manufacture drug delivery devices [FACT: Group signed a partnership with a Contract Development and Manufacturing Organisation to produce high-precision tools used to manufacture drug delivery devices] | [SOURCE: Fuyu Pres H124_m.md, p.11].
        *   Signed an MoU in 1Q2024 to be the exclusive plastics supplier for a local medical device manufacturer, with collaboration to target MedTech companies [FACT: Group signed an MoU in 1Q2024 to be the exclusive plastics supplier for a local medical device manufacturer; both parties will also collaborate to target MedTech companies] | [SOURCE: Fuyu Pres H124_m.md, p.11].
    *   **Launch of Fu Yu Biomedical:** Fu Yu Biomedical was launched in 2023 [FACT: Fu Yu Biomedical was launched in 2023, focusing on the development of high-precision devices, life sciences products, and consumables within the Medical Technology and Biotechnology sectors] | [SOURCE: Fu Yu 24 AR_m.md, p.3].

*   **Benchmarking:** No explicit competitor or industry average data for order book or new project wins is available in the provided facts.

*   **Drivers of Performance:** The 20% year-on-year increase in the order book at FY2024 end [Fu Yu 24 AR_m.md, p.6] is a strong indicator of growing customer demand and successful sales efforts. This growth is significantly driven by the Company's strategic pivot into the high-value MedTech sector, evidenced by the launch of Fu Yu Biomedical in 2023 [Fu Yu 24 AR_m.md, p.3] and the key project wins in 1H2024. These wins include manufacturing microfluidic chips for an international biomedical company, producing high-precision tools for drug delivery devices with a CDMO, and becoming an exclusive plastics supplier for a local medical device manufacturer [Fuyu Pres H124_m.md, p.11]. These initiatives leverage the capabilities of its Smart Factory [FACT: The Group's flagship Smart Factory in Singapore is one of Asia's most advanced precision manufacturing facilities] | [SOURCE: Fu Yu 24 AR_m.md, p.3] and its focus on achieving high precision levels [FACT: The Group is stabilising high-precision products at the 5-micron precision level and moving up the value chain to produce even higher levels of precision] | [SOURCE: Fu Yu 24 AR_m.md, p.7].

*   **Sustainability of Current Performance Trend:** The upward trend in order book and strategic project wins is highly sustainable, especially with the Company's clear strategic focus on growing its MedTech segment and continuously enhancing its high-precision manufacturing capabilities [Fu Yu 24 AR_m.md, p.7]. The nature of MedTech contracts (often long-term and specialized) suggests sustained demand. Continued investments in advanced manufacturing technologies (e.g., Industry 4.0 machinery, 3D printing [FACT: The integration of 3D printing and additive manufacturing technologies ensures precise material utilization, minimizing waste and enhancing cost efficiency] | [SOURCE: Fu Yu 24 AR_m.md, p.47], automation [FACT: The Group aims to increase automation levels of its toolroom to reduce downtime by 40% compared to a typical facility] | [SOURCE: Fu Yu 24 AR_m.md, p.7]) and sustainability initiatives (e.g., solar panels [FACT: Solar panels were installed on the rooftops of facilities in Johor and Penang] | [SOURCE: Fu Yu 24 AR_m.md, p.6], ERP system [FACT: Enterprise Resource Planning (ERP) integrated cloud-based IT platform completed most of its testing] | [SOURCE: Fu Yu 24 AR_m.md, p.7]) will further strengthen its competitive position and ability to secure future projects.

*   **Quantified Financial Impact:** While the direct financial impact of the order book growth isn't fully quantified in the facts, the 20% increase at FY2024 end [Fu Yu 24 AR_m.md, p.6] suggests a strong pipeline for future manufacturing revenue growth, which was 10.5% in FY2024 [Fu Yu 24 AR_m.md, p.5]. The successful securing of new MedTech projects, which typically involve high-precision components, is expected to contribute to higher-margin revenue streams, bolstering the manufacturing segment's GPM (13.5% in FY2024) [Fu Yu 24 AR_m.md, p.5] and driving continued improvements in profitability (e.g., contributing to the narrowing of net loss for continuing operations) [Fu Yu 24 AR_m.md, p.5].

*   **Due Diligence Questions:**
    1.  What is the current value of the order book, what is its expected revenue conversion timeline, and what percentage of the order book is attributed to the higher-margin MedTech segment?
    2.  Can the company provide a pipeline of potential new strategic projects in the MedTech sector and details on the competitive landscape for these high-precision manufacturing services?